Brighton Jones LLC grew its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 18.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,134 shares of the biopharmaceutical company’s stock after purchasing an additional 2,538 shares during the period. Brighton Jones LLC’s holdings in Bristol-Myers Squibb were worth $899,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in the company. Meridian Management Co. grew its holdings in Bristol-Myers Squibb by 1.5% during the first quarter. Meridian Management Co. now owns 51,770 shares of the biopharmaceutical company’s stock worth $2,815,000 after acquiring an additional 770 shares during the period. Investment Management of Virginia LLC grew its holdings in Bristol-Myers Squibb by 0.9% during the first quarter. Investment Management of Virginia LLC now owns 28,879 shares of the biopharmaceutical company’s stock worth $1,570,000 after acquiring an additional 250 shares during the period. Bbva Compass Bancshares Inc. grew its holdings in Bristol-Myers Squibb by 1.5% during the first quarter. Bbva Compass Bancshares Inc. now owns 47,772 shares of the biopharmaceutical company’s stock worth $2,598,000 after acquiring an additional 711 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in Bristol-Myers Squibb by 6.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 855,037 shares of the biopharmaceutical company’s stock worth $47,492,000 after acquiring an additional 53,474 shares during the period. Finally, Grisanti Capital Management LLC grew its holdings in Bristol-Myers Squibb by 89.2% during the first quarter. Grisanti Capital Management LLC now owns 3,690 shares of the biopharmaceutical company’s stock worth $201,000 after acquiring an additional 1,740 shares during the period. 69.51% of the stock is currently owned by institutional investors and hedge funds.
Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at $60.99 on Tuesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $66.10. The stock has a market capitalization of $99,609.57, a price-to-earnings ratio of 20.56, a PEG ratio of 2.40 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same quarter last year, the company posted $0.77 earnings per share. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. sell-side analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were given a dividend of $0.39 per share. The ex-dividend date was Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.56%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.
A number of research analysts recently weighed in on the company. Barclays PLC upped their price objective on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a report on Friday, October 13th. Jefferies Group LLC lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price objective on the stock. in a report on Monday, October 16th. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 12th. Leerink Swann upped their price objective on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday, October 23rd. Finally, Citigroup Inc. upped their price objective on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a report on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $64.93.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.